Shionogi’s COVID-19 Pill, Based On Similar Action Like Pfizer’s, Sees Around $2B In Annual Sales – Pfizer (NYSE:PFE)

Shionogi's COVID-19 Pill, Based On Similar Action Like Pfizer's, Sees Around $2B In Annual Sales - Pfizer (NYSE:PFE)

  • Japanese pharmaceutical company Shionogi & Co Ltd’s CEO believes its COVID-19, Xocova, pill can generate $2 billion in annual sales if it secures FDA approval.
  • The company expects U.S. approval by late 2024.
  • The treatment is a protease inhibitor, just like Paxlovid, the COVID-19 treatment made by Pfizer Inc PFE.
  • “I think $2 billion out of the COVID-19 market is not very difficult,” he said, basing his estimate on Pfizer’s forecast for more than $20 billion in COVID-related sales in 2023.
  • Japanese regulators granted emergency approval in November, making it the nation’s first domestically produced oral treatment for COVID.
  • CEO Isao Teshirogi told Reuters that the drug could be approved in South Korea and China as early as next month.
  • While Xocova came later to the market than Shionogi initially hoped for after Japanese regulators twice requested more data, the company says interim results of a study suggest taking the pill could lessen a patient’s chances of developing long COVID.
  • “If you kill the virus fast enough and sharp enough, the lower the probability of long COVID. That’s our hypothesis, but we need to prove that,” Teshirogi said in an interview.
  • Shionogi sold 2 million courses of Xocova, taken once daily for five days, to the Japanese government last year for ¥100 billion yen.
  • Jefferies analyst estimates that only about 11,000 courses of Xocova are consumed monthly in Japan.
  • Shionogi hopes for Xocova sales of around $1 billion to $1.5 billion this year.
  • Price Action: PFE shares are down 1.52% at $41.13 on the last check Monday
  • Photo: Image by Thomas Breher from Pixabay

Posted In:

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Posts